[Vasodilator therapy in ischemic heart disease].

Area of Science:

• Cardiology
• Pharmacology

Context:

• Investigates venodilating and veno-arterial dilating drugs in clinical and animal models.
• Focuses on patients with ischemic heart disease and left ventricular failure.
• Utilizes experimental animal models with induced arterial occlusion and myocardial infarction.

Purpose:

• To comparatively analyze the efficacy of venodilators versus veno-arterial dilators in treating cardiac dysfunction.
• To evaluate the impact of nitroglycerin, nitroprusside, and nifedipine on ischemic and infarcted myocardial segments in animal models.
• To determine optimal blood pressure targets for drug efficacy and safety in ischemic conditions.

Summary:

• Both venodilators and veno-arterial dilators similarly improved left ventricular filling pressure and cardiac index in patients.
• In animal models, nitroglycerin and nitroprusside improved segmental shortening but aggravated ischemia when systolic pressure dropped below 100 mmHg.
• Nitroglycerin and nifedipine both improved hypokinetic segments in infarcted myocardium, with differing effects on end-diastolic length.

Impact:

• Provides insights into the differential effects of vasodilators based on blood pressure levels in ischemic heart disease.
• Highlights the importance of careful blood pressure management when using potent vasodilators.
• Suggests distinct mechanisms of action for nitroglycerin and nifedipine in improving myocardial function post-infarction.